Compare ATMU & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | HAE |
|---|---|---|
| Founded | 1958 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2023 | 1991 |
| Metric | ATMU | HAE |
|---|---|---|
| Price | $52.39 | $84.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $49.00 | ★ $79.67 |
| AVG Volume (30 Days) | 845.4K | ★ 1.0M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | 11.13 | ★ 42.54 |
| EPS | 2.39 | ★ 3.44 |
| Revenue | ★ $1,724,400,000.00 | $1,327,850,000.00 |
| Revenue This Year | $6.37 | N/A |
| Revenue Next Year | $4.11 | $6.01 |
| P/E Ratio | ★ $21.87 | $24.43 |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $30.94 | $47.32 |
| 52 Week High | $53.56 | $85.23 |
| Indicator | ATMU | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 89.88 |
| Support Level | $50.30 | $80.05 |
| Resistance Level | $53.56 | $81.99 |
| Average True Range (ATR) | 1.61 | 2.08 |
| MACD | 0.39 | -0.05 |
| Stochastic Oscillator | 84.58 | 90.16 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.